Four nephrology myths debunked

Journal of Hospital Medicine

Volumn 6, Issue 5, 2011, Pages

  Rachoin, Jean Sebastien ^a   Cerceo, Elizabeth A ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Hospitalist; Myths; Nephrology

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BICARBONATE; DIURETIC AGENT; ETACRYNIC ACID; FUROSEMIDE; GLUCONATE CALCIUM; GLUTAMIC ACID; INSULIN; PARACETAMOL; PENICILLIN G; POLYSTYRENESULFONATE SODIUM; POTASSIUM; SULFA CONTAINING ANTIBIOTIC; SULFAMETHOXAZOLE; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VASOPRESSIN; VIGABATRIN;

5 OXOPROLINURIA; ACID BASE BALANCE; ADRENAL DISEASE; BEER POTOMANIA; CROSS REACTION; DELIRIUM TREMENS; DIALYSIS; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; HOMEOSTASIS; HOSPITAL PATIENT; HUMAN; HYDROXYPROLINE URINE LEVEL; HYPERKALEMIA; HYPOADRENALISM; HYPONATREMIA; HYPOTHYROIDISM; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY; KIDNEY FAILURE; METABOLIC ACIDOSIS; MYXEDEMA; NEPHROLOGY; OTOTOXICITY; PATHOPHYSIOLOGY; PENICILLIN ALLERGY; PHYSICAL EXAMINATION; POTASSIUM EXCRETION; POTASSIUM URINE LEVEL; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; TREATMENT OUTCOME; URINARY TRACT DISEASE;

ANIMALS; HUMANS; HYPERKALEMIA; HYPONATREMIA; HYPOTHYROIDISM; KIDNEY DISEASES; NEPHROLOGY;

EID: 79958743294     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.703     Document Type: Review

References (54)

1. Waikar SS, Mount DB, Curhan GC. Mortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med. 2009; 122(9): 857-865.
2. Kurtulmus N, Yarman S. Hyponatremia as the presenting manifestation of Sheehan's syndrome in elderly patients. Aging Clin Exp Res. 2006; 18(6): 536-539.
3. Pham PC, Pham PA, Pham PT. Sodium and water disturbances in patients with Sheehan's syndrome. Am J Kidney Dis. 2001; 38(3): E14.
4. Bai Y, Liu XM, Guo ZS, Dai WX, Shi YF, Zhou XY. Effect of acute water loading on plasma levels of antidiuretic hormone AVP aldosterone, ANP fractional excretion of sodium and plasma and urine osmolalities in myxedema. Chin Med J (Engl). 1990; 103(9): 704-708.
5. Asami T, Uchiyama M. Sodium handling in congenitally hypothyroid neonates. Acta Paediatr. 2004; 93(1): 22-24.
6. Baajafer FS, Hammami MM, Mohamed GE. Prevalence and severity of hyponatremia and hypercreatininemia in short-term uncomplicated hypothyroidism. J Endocrinol Invest. 1999; 22(1): 35-39.
7. Croal BL, Blake AM, Johnston J, Glen AC, O'Reilly DS. Absence of relation between hyponatraemia and hypothyroidism. Lancet. 1997; 350(9088): 1402.
8. Warner MH, Holding S, Kilpatrick ES. The effect of newly diagnosed hypothyroidism on serum sodium concentrations: a retrospective study. Clin Endocrinol (Oxf). 2006; 64(5): 598-599.
9. Gennari FJ. Disorders of potassium homeostasis. Hypokalemia and hyperkalemia. Crit Care Clin. 2002; 18(2): 273-288, vi.
10. Stevens MS, Dunlay RW. Hyperkalemia in hospitalized patients. Int Urol Nephrol. 2000; 32(2): 177-180.
11. Levraut J, Grimaud D. Treatment of metabolic acidosis. Curr Opin Crit Care. 2003; 9(4): 260-265.
12. Orringer CE, Eustace JC, Wunsch CD, Gardner LB. Natural history of lactic acidosis after grand-mal seizures. A model for the study of an anion-gap acidosis not associated with hyperkalemia. N Engl J Med. 1977; 297(15): 796-799.
13. Magner PO, Robinson L, Halperin RM, Zettle R, Halperin ML. The plasma potassium concentration in metabolic acidosis: a re-evaluation. Am J Kidney Dis. 1988; 11(3): 220-224.
14. Adrogue HJ, Lederer ED, Suki WN, Eknoyan G. Determinants of plasma potassium levels in diabetic ketoacidosis. Medicine (Baltimore). 1986; 65(3): 163-172.
15. Adrogue HJ, Madias NE. Changes in plasma potassium concentration during acute acid-base disturbances. Am J Med. 1981; 71(3): 456-467.
16. Giebisch G, Hebert SC, Wang WH. New aspects of renal potassium transport. Pflugers Arch. 2003; 446(3): 289-297.
17. Fraley DS, Adler S. Correction of hyperkalemia by bicarbonate despite constant blood pH. Kidney Int. 1977; 12(5): 354-360.
18. Blumberg A, Weidmann P, Shaw S, Gnadinger M. Effect of various therapeutic approaches on plasma potassium and major regulating factors in terminal renal failure. Am J Med. 1988; 85(4): 507-512.
19. Allon M, Shanklin N. Effect of bicarbonate administration on plasma potassium in dialysis patients: interactions with insulin and albuterol. Am J Kidney Dis. 1996; 28(4): 508-514.
20. Gutierrez R, Schlessinger F, Oster JR, Rietberg B, Perez GO. Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease. Miner Electrolyte Metab. 1991; 17(5): 297-302.
21. Kim HJ. Combined effect of bicarbonate and insulin with glucose in acute therapy of hyperkalemia in end-stage renal disease patients. Nephron. 1996; 72(3): 476-482.
22. Blumberg A, Weidmann P, Ferrari P. Effect of prolonged bicarbonate administration on plasma potassium in terminal renal failure. Kidney Int. 1992; 41(2): 369-374.
23. Carlisle EJ, Donnelly SM, Ethier JH, et al. Modulation of the secretion of potassium by accompanying anions in humans. Kidney Int. 1991; 39(6): 1206-1212.
24. Kamel KS, Wei C. Controversial issues in the treatment of hyperkalaemia. Nephrol Dial Transplant. 2003; 18(11): 2215-2218.
25. Forsythe SM, Schmidt GA. Sodium bicarbonate for the treatment of lactic acidosis. Chest. 2000; 117(1): 260-267.
26. Weisberg LS. Management of severe hyperkalemia. Crit Care Med. 2008; 36(12): 3246-3251.
27. Mizock BA, Mecher C. Pyroglutamic acid and high anion gap: looking through the keyhole? Crit Care Med. 2000; 28(6): 2140-2141.
28. Fenves AZ, Kirkpatrick HM 3rd, Patel VV, Sweetman L, Emmett M. Increased anion gap metabolic acidosis as a result of 5-oxoproline (pyroglutamic acid): a role for acetaminophen. Clin J Am Soc Nephrol. 2006; 1(3): 441-447.
29. Dempsey GA, Lyall HJ, Corke CF, Scheinkestel CD. Pyroglutamic acidemia: a cause of high anion gap metabolic acidosis. Crit Care Med. 2000; 28(6): 1803-1807.
30. Humphreys BD, Forman JP, Zandi-Nejad K, Bazari H, Seifter J, Magee CC. Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital. Am J Kidney Dis. 2005; 46(1): 143-146.
31. Yale SH, Mazza JJ. Anion gap acidosis associated with acetaminophen. Ann Intern Med. 2000; 133(9): 752-753.
32. Foot CL, Fraser JF, Mullany DV. Pyroglutamic acidosis in a renal transplant patient. Nephrol Dial Transplant. 2005; 20(12): 2836-2838.
33. Altomare E, Vendemiale G, Albano O. Hepatic glutathione content in patients with alcoholic and non alcoholic liver diseases. Life Sci. 1988; 43(12): 991-998.
34. Jewell SA, Di Monte D, Gentile A, Guglielmi A, Altomare E, Albano O. Decreased hepatic glutathione in chronic alcoholic patients. J Hepatol. 1986; 3(1): 1-6.
35. Jaeschke H, Bajt ML. Intracellular signaling mechanisms of acetaminophen-induced liver cell death. Toxicol Sci. 2006; 89(1): 31-41.
36. Persaud C, Forrester T, Jackson AA. Urinary excretion of 5-L-oxoproline (pyroglutamic acid) is increased during recovery from severe childhood malnutrition and responds to supplemental glycine. J Nutr. 1996; 126(11): 2823-2830.
37. Bonham JR, Rattenbury JM, Meeks A, Pollitt RJ. Pyroglutamicaciduria from vigabatrin. Lancet. 1989; 1(8652): 1452-1453.
38. Lyons J, Rauh-Pfeiffer A, Ming-Yu Y, et al. Cysteine metabolism and whole blood glutathione synthesis in septic pediatric patients. Crit Care Med. 2001; 29(4): 870-877.
39. Pitt JJ, Hauser S. Transient 5-oxoprolinuria and high anion gap metabolic acidosis: clinical and biochemical findings in eleven subjects. Clin Chem. 1998; 44(7): 1497-1503.
40. Rolleman EJ, Hoorn EJ, Didden P, Zietse R. Guilty as charged: unmeasured urinary anions in a case of pyroglutamic acidosis. Neth J Med. 2008; 66(8): 351-353.
41. Mizock BA, Belyaev S, Mecher C. Unexplained metabolic acidosis in critically ill patients: the role of pyroglutamic acid. Intensive Care Med. 2004; 30(3): 502-505.
42. Martensson J, Gustafsson J, Larsson A. A therapeutic trial with N-acetylcysteine in subjects with hereditary glutathione synthetase deficiency (5-oxoprolinuria). J Inherit Metab Dis. 1989; 12(2): 120-130.
43. Gruchalla RS. Diagnosis of allergic reactions to sulfonamides. Allergy. 1999; 54 Suppl 58: 28-32.
44. Tilles SA. Practical issues in the management of hypersensitivity reactions: sulfonamides. South Med J. 2001; 94(8): 817-824.
45. Knowles S, Shapiro L, Shear NH. Should celecoxib be contraindicated in patients who are allergic to sulfonamides? Revisiting the meaning of 'sulfa' allergy. Drug Saf. 2001; 24(4): 239-247.
46. Bretza JA. Thrombocytopenia due to sulfonamide cross-sensitivity. Wis Med J. 1982; 81(6): 21-23.
47. Bukhalo M, Zeitouni NC, Cheney RT. Leukocytoclastic vasculitis induced by use of glyburide: a case of possible cross-reaction of a sulfonamide and a sulfonylurea. Cutis. 2003; 71(3): 235-238.
48. Ernst EJ, Egge JA. Celecoxib-induced erythema multiforme with glyburide cross-reactivity. Pharmacotherapy. 2002; 22(5): 637-640.
49. Landor M, Rosenstreich DL. Vesiculobullous rash in a patient with systemic lupus erythematosus. Ann Allergy. 1993; 70(3): 196-203.
50. Ahmad A, Ramakrishnan A, McLean MA, et al. Use of optical biosensor technology to study immunological cross-reactivity between different sulfonamide drugs. Anal Biochem. 2002; 300(2): 177-184.
51. Cribb AE, Lee BL, Trepanier LA, Spielberg SP. Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis. Adverse Drug React Toxicol Rev. 1996; 15(1): 9-50.
52. Holtzer CD, Flaherty JF Jr, Coleman RL. Cross-reactivity in HIV-infected patients switched from trimethoprim-sulfamethoxazole to dapsone. Pharmacotherapy. 1998; 18(4): 831-835.
53. Strom BL, Schinnar R, Apter AJ, et al. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Engl J Med. 2003; 349(17): 1628-1635.
54. Earl G, Davenport J, Narula J. Furosemide challenge in patients with heart failure and adverse reactions to sulfa-containing diuretics. Ann Intern Med. 2003; 138(4): 358-359.